Overview

This trial is active, not recruiting.

Conditions rheumatoid arthritis, congenital hip dysplasia, avascular necrosis
Treatments total hip system made in china (sun, cocr, duraloc, marathon), total hip system made outside of china (summit, cocr, duraloc, marathon)
Phase phase 3
Sponsor Johnson & Johnson Medical (Suzhou) Ltd.
Start date June 2015
End date July 2017
Trial size 160 participants
Trial identifier NCT02399007, DPS-201301

Summary

A clinical trial of total Hip system used in Primary Total Hip Arthroplasty in China.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking single blind (subject)
Primary purpose treatment
Arm
(Experimental)
Patient in this arm will be implanted with Primary Total Hip Arthroplasty Devices Manufactured in China
total hip system made in china (sun, cocr, duraloc, marathon)
SUN Hip stem,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)
(Active Comparator)
Patient in this arm will be implanted with Primary Total Hip Arthroplasty Devices Manufactured Outside of China
total hip system made outside of china (summit, cocr, duraloc, marathon)
Summit Porocoat STD,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)

Primary Outcomes

Measure
Harris Hip Total Score at 12 months postoperatively
time frame: 12 months postoperatively

Secondary Outcomes

Measure
One year non-revision rate where revision is defined as removal of any component for any reason with the exception of infection
time frame: 12 months postoperatively
One year non-revision rate where revision is defined as removal of any component secondary to infection
time frame: 12 months postoperatively

Eligibility Criteria

Male or female participants from 55 years up to 80 years old.

Inclusion Criteria: 1. The subject is ≥55, and ≤80 years old 2. The Subject must be of Chinese ethnic descent and be willing to return on three occasions for clinical evaluations. 3. Subject is a suitable candidate for primary total hip replacement using the devices described in this CIP 4. Subject must meet all criteria specified in BOTH SUN hip stem and Summit hip stem instructions for use (IFU) 5. Before surgery, subject is willing and able to sign the informed consent form approved by the Institutional Review Board (IRB), Ethics Committee (EC) or Ethical Review Board (ERB). 6. Subject, in the opinion of the Clinical Investigator, is able to understand this clinical investigation and co-operate with investigational procedures. 7. Subject must be comfortable with speaking, reading, and understanding questions and providing responses in an available translated language for the patient reported outcomes (PROs) in the CIP. 8. Subject is receiving a unilateral hip replacement or, if a contralateral hip replacement is anticipated, the surgery must occur within 6 months of the first study hip. The second hip will not be enrolled in the study. Exclusion Criteria: 1. Subject does not provide written voluntary consent to participate in the clinical study. 2. The Subject is a woman who is pregnant or lactating. 3. Subjects who have undergone THA in contralateral hip within the past 6 months. 4. Contralateral hip has been enrolled in the study. 5. Presence of any previous prosthetic hip replacement device in affected hip. 6. Previous Girdlestone procedure (resection arthroplasty) or surgical fusion of the affected hip 7. Subject has hip dysplasia CROWE classification grade of 3 or 4. 8. Above knee amputation of either contralateral or ipsilateral leg 9. Subject is anticipated to require a contralateral THA between 6 months and 1-year. 10. Subject has an active infection 11. Subject has a malignant disease, severe condition, alcohol or drug addiction and/or mental disorders that the investigator believes will interfere with the study participation. 12. Subjects with severe osteoporosis, metabolic bone disease, radioactive bone disease or tumor in the bone surrounding the hip joint that, in the opinion of the investigator, will negatively impact implant fixation and the outcome of the investigation; 13. Subject has significant neurological or musculoskeletal disorders or disease that may adversely affect gait or weight bearing (e.g. muscular dystrophy, multiple sclerosis, cerebral infarction, hemiplegia, Charcot disease). 14. Subject is not comfortable with speaking, reading, and understanding questions and providing responses in an available translated language for the PROs in the CIP. 15. Subject has a medical condition with less than 2 years of life expectancy due to other medical conditions. 16. The patient has comorbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study. 17. The patient is currently participating in another investigational drug or device study. 18. Subject is a prisoner. 19. Subject has a known allergy to any component of the implant (metal for example).

Additional Information

Official title A Prospective, Randomized, Multicenter, Controlled Study Comparing the Outcomes of Primary Total Hip Arthroplasty Devices Manufactured in China Versus Devices Manufactured Outside of China
Principal investigator Shigui Yan
Description A Prospective, Randomized, Multicenter, Controlled Study Comparing the Outcomes of Primary Total Hip Arthroplasty Devices Manufactured in China versus Devices Manufactured Outside of China
Trial information was received from ClinicalTrials.gov and was last updated in May 2016.
Information provided to ClinicalTrials.gov by Johnson & Johnson Medical (Suzhou) Ltd..